VYVGART, the first-in-class FcRn blocker, now offers three administration options, including self-injection with a prefilled syringe Self-injection provides gMG and CIDP patients with flexibility for ...
– Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatment – “Today's approval reflects our ...
Xolair, an anti-immunoglobulin E antibody, is indicated for the treatment of moderate to severe persistent asthma, chronic idiopathic urticaria, and nasal polyps. The Food and Drug Administration (FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback